Theodore T. Nguyen

Theodore T. Nguyen

Auto-generated profile, based on publicly available information

Theodore T. Nguyen

Fox Chase Cancer Center 1 Cancer Signaling and Microenvironment Program Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2026 in Cancer Research Communications
Verified
Journal Article
Open access
FSFlaviane N. Silva
Flaviane N. Silva
JLJong-woo Lee
Jong-woo Lee
TNTheodore T. Nguyen
Theodore T. Nguyen
FGFiona M. Goeckel
Fiona M. Goeckel
TBTetyana Bagnyukova
Tetyana Bagnyukova
BBBarbara Ann Burtness
Barbara Ann Burtness
More than 600,000 cases of head and neck squamous cell carcinoma (HNSCC) are diagnosed globally each year. Many HNSCCs overexpress the ERBB family member epidermal growth factor receptor (EGFR), and EGFR inhibitors (EGFRi) and pan-ERBB inhibitors (ERBBi) are clinically active in the treatment of locally advanced, metastatic, or recurrent HNSCC. However, resistance to these inhibitors typically develops, often associated with epithelial–mesenchymal transition (EMT). Aurora kinase A (AURKA), a mitotic regulator with expanded signaling functions in tumors, has been reported to reverse EGFR resistance in EGFR-mutated lung cancer. To identify strategies to overcome resistance in HNSCC, we developed HNSCC cell models that were treatment-naïve parental or selected for resistance to the EGFRi erlotinib or the ERBBi afatinib. The resistant HNSCC models had typically undergone partial EMT, consistent with clinical resistance, associated with upregulation of the AURKA partner protein NEDD9. Synergy of the AURKA inhibitor VIC-1911 with erlotinib or afatinib in parental models was reduced in resistant models in short-term growth assays. In longer-term clonogenic assays and in vivo, cells selected for EGFRi/ERBBi resistance showed heightened sensitivity to VIC-1911, contributing to reduced synergy. Based on increased AURKA dependence, we compared the combination of VIC-1911 with adavosertib, an inhibitor of the cell-cycle checkpoint regulator WEE1, in parental and resistant models. These showed a combination effect both in vitro and in vivo that was retained in ERBBi-resistant xenografts, suggesting the potential value of combined AURKA and WEE1 inhibitor use in patients with ERBBi-resistant HNSCC. Significance: Treatment resistance is a major source of mortality for HNSCC. This study investigates strategies to overcome resistance to inhibitors of the ERBB family, which are commonly used for the treatment of advanced HNSCC. The results suggest the value of the use of combined AURKA and WEE inhibition in the resistance setting.

16 February 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
TNTheodore T. Nguyen
Theodore T. Nguyen
NNNitesh Kumar Nandwana
Nitesh Kumar Nandwana
YSYellamelli V.V. Srikanth
Yellamelli V.V. Srikanth
TBTetyana Bagnyukova
Tetyana Bagnyukova
OCOleksandra Chkhalo
Oleksandra Chkhalo
EGErica Golemis
Erica Golemis
Aurora kinase A (AURKA) regulates cell-cycle progression into and through mitosis. As overexpression of AURKA in cancer cells is common and associated with mitotic defects and aneuploidy, small-molecule inhibitors of AURKA have been developed as candidate therapies for cancer. However, these have typically low activity in clinical trials, with systemic toxicities limiting dose escalation. To concentrate an AURKA inhibitor in tumors, we exploited the fact that cancer cells in solid tumors selectively express high levels of the chaperone HSP90 to counteract intratumoral stresses, providing a potential targeting moiety. We developed NN-01-195 as a novel chimeric small molecule that combines an AURKA inhibitor related to TAS-119/VIC-1911 with an HSP90-binding moiety related to SNX2112 and evaluated its function. NN-01-195 tightly binds and inhibits both AURKA and HSP90 in biochemical assays. In cancer cells, NN-01-195 causes mitotic arrest and spindle abnormalities and a profile of signaling changes that closely resembles that of an AURKA inhibitor. ADME assessment indicates moderate metabolism in liver microsomes (T1/2 = 46.7 minutes) and sustained plasma exposure following single intraperitoneal injection. Maximum tolerated repeated dose testing over 5 days indicates no weight loss or toxicity at 80 mg/kg. Importantly, NN-01-195 accumulates in xenografted tumors at higher levels and for longer duration than does an AURKA inhibitor. Furthermore, in combination with an inhibitor of the G2/M checkpoint protein WEE1, NN-01-195 is more potent than VIC-1911 in limiting growth of xenograft tumors. These data support the exploration of NN-01-195 and improved analogs as promising new candidates for therapeutic evaluation.




13 August 2026
Verified
Other
Open access
FSFlaviane N. Silva
Flaviane N. Silva
JLJong-woo Lee
Jong-woo Lee
TNTheodore T. Nguyen
Theodore T. Nguyen
FGFiona M. Goeckel
Fiona M. Goeckel
TBTetyana Bagnyukova
Tetyana Bagnyukova
BBBarbara Ann Burtness
Barbara Ann Burtness
Differential expression analysis table deseq2